Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Non-Hodgkin 2 Lymphoma 2 Waldenstrom Macroglobulinemia 1 Thrombocytopenia 1 Recurrence 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neurofibromatosis 1 1 Neurofibroma, Plexiform 1 Melanoma 1 Lymphoma, T-Cell 1 Lymphoma, Mantle-Cell 1 Lymphoma, Follicular 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphoma, B-Cell 1 Lung Neoplasms 1 Hodgkin Disease 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 287 Nivolumab 258 Ipilimumab 236 Cyclophosphamide 135 aldesleukin 134 Interleukin-2 104 Temozolomide 75 Dacarbazine 74 trametinib 70 Vemurafenib 69 fludarabine 68 dabrafenib 65 fludarabine phosphate 62 sargramostim 44 binimetinib 44 Radiosurgery 44 Biopsy 43 Paclitaxel 42 Bevacizumab 42 incomplete Freund's adjuvant 39 encorafenib 37 Radiotherapy 36 Cisplatin 36 CTLA-4 Antigen 36 atezolizumab 35 Carboplatin 35 Magnetic Resonance Spectroscopy 33 cobimetinib 32 Specimen Handling 30 Introns 30

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Melanoma × Pharmacokinetics × Clear all

NCT02120222 2023-04-04

KPT-330

Ohio State University Comprehensive Cancer Center

Phase 1 Completed

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡